Image

Global Pulmonary/Respiratory Drug Delivery Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • Mar 2022
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220

Global Pulmonary/Respiratory Drug Delivery Market, By Product (Formulation Type, Device Type), Canister Type (Plain Canisters, Coated Canister), Application (Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, E-Commerce), End User (Hospitals, Clinics, Home Care Settings) – Industry Trends and Forecast to 2029

Pulmonary/Respiratory Drug Delivery Market

Global Pulmonary/Respiratory Drug Delivery Market Analysis and Size

The prevalence of chronic obstructive pulmonary disease (COPD) is on the rise. "Chronic Obstructive Pulmonary Disease (COPD) is the third greatest cause of death globally, with 3.23 million deaths in 2019," according to the WHO. The surging cases of chronic obstructive pulmonary disease (COPD) will further foster the demand for pulmonary/respiratory drug delivery, which will result in propel the market's growth and expansion over the forecasted period.

  • The pulmonary/respiratory drug delivery market was valued at USD 53,018.64 million in 2021 and is expected to reach USD 87,745.62 million by 2029, registering a CAGR of 6.5% during the forecast period of 2022-2029. The "chronic obstructive pulmonary disease (COPD)" accounts for the largest growing application segment in the pulmonary respiratory drug delivery market within the forecasted period owing to the favorable reimbursement policies for the treatment of chronic obstructive pulmonary disease (COPD) along with high incidence and mortality of this disease. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Global Pulmonary/Respiratory Drug Delivery Market Definition

Pulmonary/respiratory drug delivery basically delivers the drugs to the lung to treat respiratory tract diseases. This route is often preferred broadly because of the non-invasive approach, high blood circulation, big surface area for absorption, and permeability rate.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

By Product (Formulation Type, Device Type), Canister Type (Plain Canisters, Coated Canister), Application (Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, E-Commerce), End User (Hospitals, Clinics, Home Care Settings)

Countries Covered

U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa

Market Players Covered

GlaxoSmithKline plc (U.K.), Boehringer Ingelheim International GmbH (Germany), 3M (U.S.), AstraZeneca (U.K.), Merck & Co., Inc. (U.S.), Teva Pharmaceutical Industries Ltd., (Israel), Thermo Fisher Scientific Inc., (U.S.), Bruker (U.S.), Abbott (U.S.),  Novartis AG (Switzerland), Clarke International (U.K),  Koninklijke Philips N.V. (Netherlands),  Omron Corporation (Japan), Briggs Healthcare (U.K) and Sunovion Pharmaceuticals Inc. (U.S.)

Market Opportunities

  • Growing investments within the maket
  • Government and non-government initiatives 
  • Technological advancement associated with the pulmonary drug delivery system

Pulmonary Respiratory Drug Delivery Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail as below:

Drivers

  • Growing Respiratory Diseases

Rise in prevalence of chronic diseases such as bronchitis, tuberculosis and chronic obstructive pulmonary disease, is the most significant factor driving the growth for this market. Additionally, the rise in smoking also results in respiratory issues, which is also expected to accelerate the market's overall growth.

  • Advantages over conventional drug delivery approaches

The pulmonary/respiratory drug delivery systems are ideal drug approaches compared to conventional drug delivery approaches. There are various limitations associated with traditional therapy such as late-onset of action and low efficacy. Furthermore, the benefits associated with the pulmonary/respiratory drug delivery system, such as the large surface area present in alveolar sacs, high drug loading efficiency and high vascularization which makes lung an appropriate site for drug absorption are expected to boost the market's growth.

Moreover, the rising awareness among the patients and doctors regarding chronic diseases also cushions the market's growth within the forecasted period. The recent advancements in pulmonary drug delivery devices and methods and minimum dose requirements are also projected to bolster the growth of the market.

Opportunities

  • Growing Awareness and Advancements

Moreover, the technological advancement associated with the pulmonary drug delivery system coupled with government and non-government initiatives to increase awareness regarding respiratory issues are estimated to generate lucrative opportunities for the market. Various investments by government and non-government organizations will further offer numerous growth opportunities for the market.

Restraints/Challenges Global Pulmonary/Respiratory Drug Delivery Market

  • Regulatory Issues

On the other hand, the regulatory issues related to the approval of pulmonary drug delivery systems is expected to obstruct market growth.

  • High Pricing Pressures

Also, the high pricing pressures are projected to challenge the pulmonary respiratory drug delivery market in the forecast period of 2022-2029.

Moreover, the poor formulation stability for drugs along with the improper dosing reproducibility will impede the growth of the market

This pulmonary/respiratory drug delivery market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pulmonary respiratory drug delivery market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Post Covid-19 Impact on Pulmonary/Respiratory Drug Delivery Market

The pulmonary/respiratory drug delivery market was immensely impacted by the outbreak of COVID-19. The COVID-19 epidemic has put a strain on healthcare systems around the world, necessitating the creation of new diagnostic tools and treatment centers for people. A large number of clinics and hospitals across the globe have been restructured to expand hospital capacity for COVID-19 patients, which could lead to future growth in the hospitalized inhalation medication delivery industry. The increment in number of hospitals will also increase the number of diseases diagnosed.

The patients suffering from the diseases such as asthma and COPD are considered at increased risk of dying from COVID-19. The COVID-19 pandemic may have affected patients' responses to respiratory symptoms, which has substantially contributed to the global market's expansion.

Recent Developments

  • In June 202o, The Japanese Ministry of Health, Labour, and Welfare (MHLW) approved additional therapy alternatives for Japanese patients at the same time, according to Novartis Pharma K.K. ("Novartis Pharma"). TabrectaTM (capmatinib, formerly INC280), an oral MET inhibitor, is used to treat advanced and/or recurrent unresectable non-small cell lung cancer (NSCLC) with a METex14 mutation (NSCLC).
  • In September 2020, UPTRAVI® (selexipag) as an intravenous (IV) injection for the treatment of pulmonary arterial hypertension was submitted to the US Food and Drug Administration (FDA) by Johnson & Johnson's Janssen Pharmaceutical Companies.

Global Pulmonary/Respiratory Drug Delivery Market Scope

The pulmonary/respiratory drug delivery market is segmented on the basis of product, canister type, application, distribution channel and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

  • Formulation Type
  • Device Type

On the basis of product, the pulmonary/respiratory drug delivery market is segmented into formulation type and device type. Formulation type is sub-segmented into suspension, aerosol, solution aerosol and dry powder formulation. Device type is sub-segmented into metered dose inhalers (MDI), dry powder inhalers (DPI) and nebulizers.

Canister Type

  • Plain Canisters
  • Coated Canister

On the basis of canister type, the pulmonary/respiratory drug delivery market is segmented into plain canisters and coated canister.

Application

  • Chronic Obstructive Pulmonary Disease
  • Asthma
  • Cystic Fibrosis

On the basis of application, the pulmonary/respiratory drug delivery market is segmented into chronic obstructive pulmonary disease, asthma and cystic fibrosis. The chronic obstructive pulmonary disease (COPD) segment is expected to show the highest growth owing to the favorable reimbursement policies for the treatment of chronic obstructive pulmonary disease (COPD) and the high incidence and mortality of this disease.

Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • E-Commerce

On the basis of distribution channel, the pulmonary/respiratory drug delivery market is segmented into retail pharmacies, hospital pharmacies and e-commerce.

End User

  • Hospitals
  • Clinics
  • Home Care Settings

On the basis of end user, the pulmonary/respiratory drug delivery market is bifurcated into hospitals, clinics and home care settings.

Pulmonary/Respiratory Drug Delivery Market Regional Analysis/Insights

The pulmonary/respiratory drug delivery market is analyzed and market size insights and trends are provided by country, product, canister type, application, distribution channel and end user as referenced above.

The countries covered in the pulmonary/respiratory drug delivery market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the pulmonary/respiratory drug delivery market because of the presence of major key players and growing demand for diagnostic devices such as PDDS along with the increase in the level of disposable income and surging incidences of various diseases, including asthma, chronic obstructive pulmonary disease (COPD) and others within the region.

 Asia-Pacific is expected to witness significant growth during the forecast period of 2022 to 2029 due to the growing number of patients who have asthma and allergic rhinitis, surging number of research and development activities and increasing awareness by public-private organizations within the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The pulmonary/respiratory drug delivery market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for pulmonary respiratory drug delivery market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the pulmonary respiratory drug delivery market. The data is available for historic period 2010-2020.

Competitive Landscape and Pulmonary/Respiratory Drug Delivery Market Share Analysis

The pulmonary/respiratory drug delivery market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pulmonary/respiratory drug delivery market.

Some of the major players operating in the pulmonary/respiratory drug delivery market are

  • GlaxoSmithKline plc (U.K.)
  • Boehringer Ingelheim International GmbH (Germany)
  • 3M (U.S.)
  • AstraZeneca (U.K.)
  • Merck & Co., Inc (U.S.)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Thermo Fisher Scientific Inc (U.S.)
  • Bruker (U.S.)
  • Abbott (U.S.)
  • Novartis AG (Switzerland)
  • Clarke International (U.K)
  • Koninklijke Philips N.V. (Netherlands)
  • Omron Corporation (Japan)
  • Briggs Healthcare (U.K)
  • Sunovion Pharmaceuticals Inc (U.S.)

Research Methodology : Global Pulmonary/Respiratory Drug Delivery Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-pulmonary-respiratory-drug-delivery-market

Customization Available : Global Pulmonary/Respiratory Drug Delivery Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The Pulmonary/Respiratory Drug Delivery Market is Expected to Show a Value of USD 87,745.62 million by 2029.
The Pulmonary/Respiratory Drug Delivery Market is Estimated to Register a CAGR of 6.5% During the Forecast Period of 2022 to 2029.
The Major Companies Operating in the Pulmonary/Respiratory Drug Delivery Market are GlaxoSmithKline plc (U.K.), Boehringer Ingelheim International GmbH (Germany), 3M (U.S.), AstraZeneca (U.K.), Merck & Co., Inc. (U.S.) and Teva Pharmaceutical Industries Ltd., (Israel).
The Countries Covered in the Pulmonary/Respiratory Drug Delivery Market Report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
The Pulmonary/Respiratory Drug Delivery Market Report Curated by the Data Bridge Market Research Team Includes In-Depth Expert Analysis, Patient Epidemiology, Pipeline Analysis, Pricing Analysis, and Regulatory Framework.